Log in

Relevant bibliographies by topics / Buserelin acetate / Journal articles

To see the other types of publications on this topic, follow the link: Buserelin acetate.

Journal articles on the topic 'Buserelin acetate'

Author: Grafiati

Published: 4 June 2021

Last updated: 8 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Buserelin acetate.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Huanca, W. F., C. Mamani, and W. Huanca. "165 EFFECT OF INJECTION OF SEMINAL PLASMA ON OVULATION RATE, CORPUS LUTEUM DEVELOPMENT, AND SENSITIVITY TO PROSTAGLANDIN IN ALPACAS (VICUGNA PACOS)." Reproduction, Fertility and Development 27, no. 1 (2015): 173. http://dx.doi.org/10.1071/rdv27n1ab165.

Full text

Abstract:

The seminal plasma (SP) of camelids contains a protein identified as β Nerve Growth Factor with capacity of induced ovulation and develop a corpus luteum. A study was designed to evaluate the effect of application of SP on the interval of time from injection of stimulus to the ovulation and corpus luteum (CL) size (Experiment 1, n = 24) and on the sensitivity of CL to the injection of prostaglandin (196 µg of tiaprost) (PG) at different periods from ovulation (Experiment 2, n = 86). Exp. 1: Adult female alpacas with presence of a follicle ≥7 mm were assigned to the application of 1 mL of SP via IM (T: n = 12) or application of 50 µg of acetate of busereline IM (T2: n = 12). Exp. 2: Alpacas with presence of a follicle ≥7 mm were induced to ovulation with 50 µg of acetate of busereline or 1 mL IM of SP. Animals were evaluated by ultrasound to confirm the ovulation and were assigned to the following treatment: T1 (n = 8): SP + PG Day 4; T2 (n = 8): buserelin acetate + PG Day 4; T3 (n = 8): SP + PG Day 5; T4 (n = 8): buserelin acetate + PG Day 5; T5 (n = 8): SP + PG Day 6; T6 (n = 8): buserelin acetate + PG Day 6; T7 (n = 8): SP + PG Day 7; T8 (n = 8): buserelin acetate + PG Day 7; T9 (n = 8): SP + PG Day 8; T10 (n = 8): buserelin acetate + PG Day 8 and T11 (n = 6) (Control): Application of 1 mL of saline solution. The animals were evaluated by ultrasound with an Aloka SSD500 (Aloka, Tokyo, Japan) and 7.5-MHz linear transducer each 2 h (Exp. 1) and each 12 h (Exp. 2) after of application of PG. In Exp. 1, the ovulation rate was 95.7% to T1 and T2 and an interval of time between injection of stimulus and ovulation was 27.4 ± 2.5 h and 26.8 ± 1.8 to T1 and T2, respectively. In Exp. 2, luteolysis was 0.0%, 0.0%, 25.0%, 0.0%, 100.0%, 100.0%, 100.0%, 100.0%, 100.0%, 100.0%, and 0.0% for the treatments T1, T2, T3, T4, T5, T6, T7, T8, T9, T10, and T11 respectively. The results suggest that no differences exist between in the ovulation rate and interval to the ovulation between the application of buserelin acetate or SP and that the CL was sensible at Day 5 to the prostaglandin respect SP and with similar response to the sensibility of CL from Day 6 to Day 8.

APA, Harvard, Vancouver, ISO, and other styles

2

D’Hondt, Matthias, Frederick Verbeke, Pieter Wuytens, Andre Skirtach, Bart De Spiegeleer, and Evelien Wynendaele. "Hot-melt Preparation of a Non-biodegradable Peptide Implant: A Proof of Principle." Protein & Peptide Letters 26, no. 9 (September 16, 2019): 691–701. http://dx.doi.org/10.2174/0929866526666190619113724.

Full text

Abstract:

Background: Both biodegradable and non-biodegradable peptide-loaded implants are already developed for the long-term treatment of patients, thereby reducing the frequency of drug administration. To further improve peptide formulation, extending the scope of implant-based drug delivery systems towards other polymers and processing techniques is highly interesting. Objective: In this study, as a proof-of-principle, the feasibility of hot-melt processing of a peptide active pharmaceutical ingredient was assessed by developing a non-biodegradable poly(ethylenevinyl acetate) (33% VA) implant loaded with 20% (w/w) buserelin acetate. Methods: Cross-sectional implant characterization was performed by Raman microscopy. The stability of buserelin acetate in the polymeric matrix was evaluated for 3 months under ICH stability conditions and the quantity as well as the degradation products analyzed using LC-UV methods. An in vitro dissolution study was performed as well and buserelin acetate and its degradants analyzed using the same chromatographic methods. Results: No significant quantities of buserelin acetate-related degradation products were formed during the hot-melt preparation as well as during the stability study. Together with the consistent buserelin acetate assay values over time, chemical peptide stability was thus demonstrated. The in vitro buserelin acetate release from the implant was found to be diffusion-controlled after an initial burst release, with stable release profiles in the stability study, demonstrating the functional stability of the peptide implant. Conclusion: These results indicate the feasibility of preparing non-biodegradable peptide-loaded implants using the hot-melt production method and may act as a proof of principle concept for further innovation in peptide medicinal formulations.

APA, Harvard, Vancouver, ISO, and other styles

3

Goulding, A., and E. Gold. "Norethindrone acetate only partially protects the skeleton of rats treated with the LHRH agonist buserelin from oestrogen-deficiency osteopaenia." Journal of Endocrinology 137, no. 1 (April 1993): 27–33. http://dx.doi.org/10.1677/joe.0.1370027.

Full text

Abstract:

ABSTRACT In women with endometriosis there is concern that therapeutic use of LH-releasing hormone (LHRH) analogues, to lower ovarian oestrogen production and control endometrial hyperplasia, leads to unwanted oestrogen-deficiency bone loss. We have developed an animal model of this LHRH-mediated oestrogen-deficiency bone loss in the rat, using buserelin. The aim was to use this model to determine whether the progestogen, norethindrone acetate, could counter oestrogen-deficiency bone loss associated with prolonged treatment with the LHRH agonist buserelin. Four groups of animals which had their bones labelled with 45Ca were studied for 4 weeks: group A, control; group B, buserelin treated; group C, norethindrone acetate treated; group D, norethindrone acetate + buserelin treated. Buserelin was given daily (19·2 pmol/kg body wt); norethindrone was given orally three times / week (1·47 μmol/kg body wt). Bone resorption was monitored by measuring the urinary excretion of hydroxyproline and 45Ca and bone 45Ca content. Buserelin-treated rats developed similarly depressed plasma oestradiol-17β values in the presence and absence of progestogen, and both groups given buserelin had significantly smaller uteri than controls or rats given norethindrone without buserelin. However, norethindrone did not prevent buserelin-mediated increases in bone resorption. At the end of the study total body calcium values (mean ± s.d.) in the four groups were (mg) respectively; 2594 ± 123; 2260 ± 92 (P < 0·001 compared with controls); 2616 ± 221; 2415 ± 130 (P < 0·02 compared with controls). Rats given norethindrone and buserelin in combination had higher values (P < 0·02) than animals given buserelin alone, but significantly less total body calcium than controls (P < 0·02). We conclude that progestogen confers partial, but not complete, protection of the skeleton of buserelin-treated rats from oestrogen-deficiency bone loss. Journal of Endocrinology (1993) 137, 27–33

APA, Harvard, Vancouver, ISO, and other styles

4

Wätzig, Hermann, and Matthias Degenhardt. "Characterisation of buserelin acetate by capillary electrophoresis." Journal of Chromatography A 817, no. 1-2 (August 1998): 239–52. http://dx.doi.org/10.1016/s0021-9673(98)00443-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Schroeder, Fritz H., Tycho M. T. W. Lock, Dev R. Chadha, Frans M. J. Debruyne, Herbert F. M. Karthaus, Frank H. de Jong, Jan G. M. Klijn, Ans W. Matroos, and Herman J. de Voogt. "Metastatic Cancer of the Prostate Managed with Buserelin Versus Buserelin Plus Cyproterone Acetate." Journal of Urology 137, no. 5 (May 1987): 912–18. http://dx.doi.org/10.1016/s0022-5347(17)44293-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kono, T., M. Ishii, and S. Taniguchi. "Intranasal buserelin acetate-induced pigmented roseola-like eruption." British Journal of Dermatology 143, no. 3 (September 2000): 658. http://dx.doi.org/10.1111/j.1365-2133.2000.03737.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Tanaka, H., Y. Shimizu, H. Sato, O. Takahashi, H. Ota, and T. Tanaka. "The reduced-dosage buserelin acetate therapy for leiomyoma." Fertility and Sterility 77 (February 2002): S53. http://dx.doi.org/10.1016/s0015-0282(01)03188-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Pinto, Tássia Louregiani Carvalho, Marina Bottrel Reis Nogueira, José Nélio de Sousa Sales, Rafaela Rodrigues de Carvalho, Robert Andrew Cushman, and José Camisão de Souza. "FACTORS AFFECTING PREGNANCY RATES AFTER OVUM PICK UP-DERIVED EMBRYO TRANSFER IN LACTATING HOLSTEIN RECIPIENTS UNDER TROPICAL CONDITIONS." Ciência e Agrotecnologia 39, no. 5 (October 2015): 498–505. http://dx.doi.org/10.1590/s1413-70542015000500008.

Full text

Abstract:

ABSTRACTHigh milk production, heat, physiological status and management impair reproduction in Holstein cows. The use of in vivo-produced embryos has been reported as an alternative to enhance pregnancy outcome in the tropics; however there are several limitations for its production, especially from variations in superovulatory responses. The in vitro production of embryos would avoid such variations, but few studies have been reported. This study aims to verify the effects of variables related to recipients under a program of routine in vitro embryo transfer on a commercial dairy farm in southeastern Brazil. It was hypothesized that pregnancy rates after transfer of ovum pick up or OPUderived embryos (ET) to lactating Holstein recipients may be influenced by recipient GnRH-treatment at ET, parity, milk production and body condition score. Recipients (267) were allocated to one of three i.m. treatments given at ET: Control (92) - 2.5 ml saline; Buserelin (86) - 10 μg Buserelin acetate; Deslorelin (89) - 750 μg Deslorelin acetate. Ultrasound images and blood samples were taken at ET and seven days later. The first pregnancy diagnosis was performed between 30-40 days and the second between 60-80 days post ET. Data were analyzed by GENMOD (SAS(r)). The proportion of pregnant cows was greater (P<0.05) in Buserelin-treated recipients (38.3%) at the first pregnancy diagnosis than Controls (24.1%), but similar to Deslorelin and control cows at the second diagnosis (13.0, 20.9 and 14.6% in Control, Buserelin and Deslorelin, respectively). In conclusion, Buserelin improved pregnancy rate only transitorily, under the present conditions.

APA, Harvard, Vancouver, ISO, and other styles

9

Ewuola, E. O., G. A. Omotosho, and A. A. Adeyemi. "Effects of Buserelin acetate and semen extension on fertility in rabbit does under artificial insemination." Nigerian Journal of Animal Production 44, no. 1 (December 24, 2020): 130–35. http://dx.doi.org/10.51791/njap.v44i1.503.

Full text

Abstract:

The productivity of rabbit farms can be increased and become more homogeneous through the use of Artificial Insemination (AI). However, this possibility is limited with low conception in artificially inseminated does without ovulation induction. This study aimed at determining the conception rate of rabbit does induced with buserelin acetate and inseminated with extended semen at varied dilution ratio. A total number of Twenty eight multiparous non-lactating rabbit does were randomly allotted into four treatments housed individually in a completely randomised design. Rabbits were used as a teaser for semen collection using an artificial vagina and after semen collection and evaluation; ejaculates from ten bucks with more than 60% motility were pooled and extended. Forty eight hours before the AI, the does were hormonally synchronized (i.m) for oestrus with 20IU PMSG. Does in treatment 1(control) were inseminated with unextended semen without buserelin but injected with normal saline, while does on treatments 2, 3 and 4 were inseminated with extended semen in ratio 1: 1, 1:2 and 1: 3 (semen: extender), respectively and were all intramuscularly induced using 0.8µg of buserelin after insemination. Results showed that some of the does induced with buserelin acetate intramuscularly (treatments 2, 3 and 4) were pregnant, while none of the control rabbits was pregnant. The ratio 1: 1 extended semen (treatment 2) recorded the highest percentage conception (85.71%) followed by treatment 3 (71.43%) and treatment 4 (57.14%). There was significant (P<0.05) difference in gestation length (32.50, 31.00 and 32.75), litter size (4.83, 8.60 and 3.25), live kits at birth (3.50, 6.60 and 1.75) for treatments 2, 3 and 4 respectively and the average litter weight was not significantly different among the treatments. This study suggests that diluting semen in ratio 1: 1 produced highest conception rate with intramuscular administration of 0.8µg buserelin acetate than extending semen in ratios 1: 2 and 1: 3.

APA, Harvard, Vancouver, ISO, and other styles

10

Vicente, J. S., R. Lavara, F. Lavara, F. Marco-Jiménez, and M. P. Viudes-de-Castro. "Rabbit reproductive performance after insemination with buserelin acetate extender." Livestock Science 115, no. 2-3 (June 2008): 153–57. http://dx.doi.org/10.1016/j.livsci.2007.07.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Crijns, M. B., F. W. Jansen, C. G. Van Praag, and J. G. van der Schroeff. "Immediate-type reaction to buserelin acetate in a nasal spray." Contact Dermatitis 25, no. 3 (September 1991): 189. http://dx.doi.org/10.1111/j.1600-0536.1991.tb01827.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Polson, David W., Vivien MacLachlan, Jennifer A. Krapez, Carl Wood, and David L. Healy. "A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate*) for folliculogenesis in routine in vitro fertilization patients*Buserelin acetate Suprefact Hoechst Melbourne, Victoria, Australia." Fertility and Sterility 56, no. 3 (September 1991): 509–14. http://dx.doi.org/10.1016/s0015-0282(16)54550-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Nara, Nobuo, and Shuji Tohda. "Successful Treatment of Refractory Pure Red Cell Aplasia by Buserelin Acetate." Acta Haematologica 92, no. 1 (1994): 42–45. http://dx.doi.org/10.1159/000204137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Konzen-Freitas, Andreia Regina, Joadil Gonçalves de Abreu, Janessa Sampaio de Abreu, Vágner Luiz de Queiroz Dantas, Ruy Alberto Caetano Corrêa Filho, and Jayme Aparecido Povh. "Tambaqui females (Colossoma macropomum) spawn after hormonal induction with buserelin acetate." Animal Reproduction Science 221 (October 2020): 106594. http://dx.doi.org/10.1016/j.anireprosci.2020.106594.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Usami, Makiko, Kazumasa Misawa, Naomi Yagi, Hitoshi Sekikawa, and Toshitaka Nabeshima. "Buserelin acetate microparticle dispersion effects drug release and plasma E1 levels." International Journal of Pharmaceutics 339, no. 1-2 (July 2007): 130–38. http://dx.doi.org/10.1016/j.ijpharm.2007.02.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

IMAI, Keiji, Masaru IWASAKI, Naoki MITSUHASHI, and Eiji MARUI. "Economic Analysis of Buserelin Acetate Therapy in the Treatment of Myoma Uteri." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 28, no. 1 (1997): 35–47. http://dx.doi.org/10.3999/jscpt.28.35.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Lopez, Massimo, Maurilio Natali, Luigi Di Lauro, Patrizia Vici, Francesco Pignatti, and Silvia Carpano. "Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer." Cancer 72, no. 2 (July 15, 1993): 502–5. http://dx.doi.org/10.1002/1097-0142(19930715)72:2<502::aid-cncr2820720228>3.0.co;2-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Espinales, Alan, Jonathan Reyes, and Auberto Hidalgo. "Effect of three concentrations of buserelin acetate on the emission of gametes from Cynoscion analis." Manglar 15, no. 2 (December 31, 2018): 99–106. http://dx.doi.org/10.17268/manglar.2018.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Lopes, Tania P., Lorena Padilla, Alfonso Bolarin, Heriberto Rodriguez-Martinez, and Jordi Roca. "Weaned Sows with Small Ovarian Follicles Respond Poorly to the GnRH Agonist Buserelin." Animals 10, no. 11 (October 28, 2020): 1979. http://dx.doi.org/10.3390/ani10111979.

Full text

Abstract:

The GnRH agonist buserelin (GnRH), used to synchronize ovulation in weaned sows, attains only 70–80% effectivity, owing to several reasons of ovarian origin. This study evaluated in particular whether mean ovarian follicle size at treatment and the season of weaning are among those influencing GnRH responsiveness. The experiment was carried out in a temperate-region farm with 352 sows of 1–6 parities weaned either in winter–spring (WS, 174 sows) or in summer–autumn (SA, 178 sows). The sows were randomized into two groups: GnRH (10 µg of buserelin acetate at 86 h after weaning, 172 sows) and control (180 sows). The ovaries were transrectally scanned from weaning to ovulation and the sows clustered according to their mean follicular size at treatment time: small (<0.5 cm in diameter), medium (0.5 to 0.64 cm) and large (0.65 to 1.09 cm). In total, 88.33% of the GnRH-treated sows ovulated, with 82% of them within the expected time window (120–132 h after weaning). In contrast, 95.45% of the unresponsive sows had small follicles at the time of treatment and were mostly weaned in SA (20.45%) than in WS (4.76%). In conclusion, the conspicuous presence of sows having small ovarian follicles at treatment time compromises the efficiency of the GnRH agonist buserelin to synchronize ovulation in weaned sows, which occurs more frequently in summer–autumn weaning.

APA, Harvard, Vancouver, ISO, and other styles

20

Vicente, J. S., R. Lavara, F. Marco-Jiménez, and M. P. Viudes-de-Castro. "Detrimental effect on availability of buserelin acetate administered in seminal doses in rabbits." Theriogenology 76, no. 6 (October 2011): 1120–25. http://dx.doi.org/10.1016/j.theriogenology.2011.05.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Chenault, J. R., D. D. Kratzer, R. A. Rzepkowski, and M. C. Goodwin. "LH and FSH response of Holstein heifers to fertirelin acetate, gonadorelin and buserelin." Theriogenology 34, no. 1 (July 1990): 81–98. http://dx.doi.org/10.1016/0093-691x(90)90579-i.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Aiudi, G., M. Albrizio, G. De Vico, A. Scirpo, S. Cristarella, and M. Cinone. "261 FERTILITY CONTROL BY GnRH ANALOGUES IN DOGS." Reproduction, Fertility and Development 17, no. 2 (2005): 280. http://dx.doi.org/10.1071/rdv17n2ab261.

Full text

Abstract:

GnRH plays a pivotal role in reproduction by stimulating the release of gonadotrophins. Chemical substitutions in the GnRH molecule lead to analogues possessing antagonist or agonist activity (Paramo RM et al. 1993 J. Reprod. Fertil. Suppl. 47, 387–397). The highly potent agonist analogue, Buserelin, with up to 20 times of potency, by increasing binding affinity, desensitizing competitive receptors, and resisting metabolic degradation, shuts down rather than stimulates reproductive function (Bertschinger HJ et al. 2001 J. Reprod. Fertil. Suppl. 57, 275–283). In man, Buserelin is employed in several gonadal hormone-dependent diseases and for prostatic cancers. We suppress gonadal function in male dogs using Buserelin. Eight intact male German sheep dogs 20 months old were divided into two groups; A, 4 subjects treated for pharmacological castration (Buserelin acetate, 0.3 mg/each, s.c., every 8 h for 30 days) (Suprefact-Aventis Pharma, Italy); B, 4 subjects treated with placebo (NaCl, 0.9%, s.c., every 8 h for 30 days). Plasma testosterone concentrations were measured twice a week by RIA using commercial kits (Coat-A-Count, Los Angeles, USA). Clinical examination of the male genital tract was conducted by ultrasound monitoring. Before and after the pharmacological treatment, semen was collected and evaluated for macroscopic and microscopic parameters. After treatment, testicular specimens were collected by orchiectomy, fixed in Bouin's solution, and embedded in paraffin wax. Thin sections were cut and stained with hematoxylin/eosin. The presence of germ cells (spermatogonia to spermatozoa, Sertoli and Leydig cells number) were analyzed. Randomly selected fields of transverse and longitudinal sections of seminiferous tubules were observed and analyzed using a computer assisted image analyzer (MONO system, Italy). The images acquired were segmented and binarized in order to obtain the masks of the tubular profiles; the mean values of the area, major and minor axes, mean diameter, and perimeter occupied by the testicular tubules were calculated automatically. Data were analyzed by ANOVA test. After Buserelin, all dogs (group A) showed a reduction in testicular and prostatic diameters compared to group B. Azoospermia was observed in group A. Histological examination revealed a statistically significant cell reduction of the germinal line (spermatogonia and spermatocytes, P < 0.05; spermatids and spermatozoa, P < 0.001). GnRH pharmacological treatment induced a cessation of normal spermatogenesis at the spermatocyte level while no statistical difference in morphometric parameters of seminiferous tubules were observed. The basic testosterone level (3.2 ± 1.3 ng/mL) rose to 12 ± 3.7 ng/mL (21° day) and than shut down to 0.5 ± 0.3 ng/mL (30° day), giving a long-term suppression. The present study demonstrates that Buserelin is an anti-fertility agent that gives suppression of reproductive function in male dogs. The method may have a clinical application. The utilization of a Buserelin depot will be a successive step.

APA, Harvard, Vancouver, ISO, and other styles

23

Kuz’mina, N. E., S. V. Moiseev, and A. I. Luttseva. "The Problem of Dynamic Process Manifestation in Identification of Organic Compounds by NMR Spectroscopy." Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 10, no. 1 (February 26, 2020): 63–76. http://dx.doi.org/10.30895/1991-2919-2020-10-1-63-76.

Full text

Abstract:

The number, shape and position of NMR spectral lines depend on dynamic processes, and this creates certain difficulties in identification of pharmaceutical substances by NMR spectroscopy. The aim of the paper was to study instances of manifestation of intramolecular dynamic processes that affect identification of organic compounds by NMR, and to illustrate the potential of the methods used for their reduction, as well as associated problems.Materials and methods: 1H and 13C spectra of the following pharmaceutical substances: «buserelin acetate», «valsartan», «goserelin acetate», «iopromide», «clopidogrel hydrogensulfate», «omeprazole», «proroxan», «risperidone», «triptorelin acetate», and «enalapril maleate» were used to demonstrate negative effects of dynamic processes. The spatial structures of conformers were established by 1H-1H ROESY experiments. The quantum-chemical calculation of geometric and thermodynamic characteristics of different conformers was carried out by the PM3 method, and electronic characteristics—by the AM1 method with the help of the HyperChem software.Results: the authors analysed intramolecular dynamic processes which are most commonly encountered in expert work: pyramidal inversion of nitrogen in a heterocyclic compound (risperidone, proroxan, clopidogrel), rotation of molecular fragments around the amide bond (valsartan, iopromide, enalapril), prototropic rearrangements (buserelin, goserelin, omeprazole, triptorelin). The change in exchange rates was explained from the perspective of the change in the system of intra- and intermolecular nonvalent interactions.Conclusions: the use of traditional methods for increasing the rate of dynamic processes (increasing the temperature and changing the solvent) does not always eliminate the negative effects of intramolecular transformations. Methods of smoothing the spectral manifestations of dynamic processes have limited application due to strong intramolecular nonvalent interactions which prevent the conversion of the dynamic process rate into fast exchange. Experts and manufacturers should take into account the manifestation of dynamic processes during identification of pharmaceutical substances by NMR spectroscopy.

APA, Harvard, Vancouver, ISO, and other styles

24

Fedele, Luigi, Maurizio Marchini, Stefano Bianchi, Andrea Baglioni, and Fabrizio Zanotti. "Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study." Fertility and Sterility 59, no. 6 (June 1993): 1191–95. http://dx.doi.org/10.1016/s0015-0282(16)55975-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Kuz’mina, N. E., S. V. Moiseev, V. I. Krylov, A. S. Deryabin, V. A. Yashkir, and V. A. Merkulov. "Validation of an NMR-Spectroscopic Method for Authenticity Confirmation of Buserelin Acetate Pharmaceutical Substance." Pharmaceutical Chemistry Journal 52, no. 2 (May 2018): 159–65. http://dx.doi.org/10.1007/s11094-018-1783-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Yingsukwattana, Koson, Satit Puttipipatkhachorn, Uracha Ruktanonchai, and Narong Sarisuta. "Enhanced permeability across Caco-2 cell monolayers by specific mannosylating ligand of buserelin acetate proliposomes." Journal of Liposome Research 26, no. 1 (May 6, 2015): 69–79. http://dx.doi.org/10.3109/08982104.2015.1039030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Vollenhoven, Beverley J., Paul Shekleton, Jillian McDonald, and David L. Healy. "Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women." Fertility and Sterility 54, no. 6 (December 1990): 1032–38. http://dx.doi.org/10.1016/s0015-0282(16)54001-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Marchini, Maurizio, Luigi Fedele, Stefano Bianchi, Gabriele Angelo Losa, Morena Ghisletta, and Giovanni Battista Candiani. "Secretory changes in preovulatory endometrium during controlled ovarian hyperstimulation with buserelin acetate and human gonadotropins." Fertility and Sterility 55, no. 4 (April 1991): 717–21. http://dx.doi.org/10.1016/s0015-0282(16)54236-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Swarovsky, B., M. Wolf, K. Havemann, and R. Arnold. "Tamoxifen or Cyproterone Acetate in Combination with Buserelin Are Ineffective in Patients with Pancreatic Adenocarcinoma." Oncology 50, no. 4 (1993): 226–29. http://dx.doi.org/10.1159/000227184.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Camillo, F., M. Pacini, D. Panzani, I. Vannozzi, Al Rota, and G. Aria. "Clinical Use of Twice Daily Injections of Buserelin Acetate to Induce Ovulation in the Mare." Veterinary Research Communications 28 (2004): 169–72. http://dx.doi.org/10.1023/b:verc.0000045398.62134.e4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Goldman, J. A., D. Dicker, D. Feldberg, J. Ashkenazi, and I. Voliowich. "A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization–embryo transfer." Human Reproduction 9, no. 2 (February 1994): 226–28. http://dx.doi.org/10.1093/oxfordjournals.humrep.a138486.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Yoshimura, Yukari, Sakae Goto, Hiromi Hashimoto, Yoko Izumi, Yuko Kasahara, Motoko Eguchi, Eriko Komori, et al. "Effectiveness of Buserelin Acetate for Triggering Endogenous LH Surge before Oocyte Retrieval in Clomiphene Citrate Cycle." Journal of Mammalian Ova Research 24, no. 2 (April 2007): 61–64. http://dx.doi.org/10.1274/jmor.24.61.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Mizera, Alicja, Marian Kuczaj, Anna Szul, and Jarosław Jędraszczyk. "Effect of addition of buserelin acetate to the extender on motility and viability of bovine spermatozoa." Animal Biotechnology 30, no. 2 (December 31, 2018): 99–104. http://dx.doi.org/10.1080/10495398.2018.1521821.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

do Nascimento, Nivaldo Ferreira, Regiane Cristina da Silva, Fernanda Nogueira Valentin, Maria do Carmo Faria Paes, Marta Verardino De Stéfani, and Laura Satiko Okada Nakaghi. "Efficacy of buserelin acetate combined with a dopamine antagonist for spawning induction in the bullfrog (Lithobates catesbeianus)." Aquaculture Research 46, no. 12 (May 9, 2014): 3093–96. http://dx.doi.org/10.1111/are.12461.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

BORȘ, Silviu Ionut, Iulian IBĂNESCU, Șteofil CREANGĂ, and Alina BORȘ. "Reproductive performance in dairy cows with cystic ovarian disease after single treatment with buserelin acetate or dinoprost." Journal of Veterinary Medical Science 80, no. 7 (2018): 1190–94. http://dx.doi.org/10.1292/jvms.17-0690.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Emre, Birten, İbrahim Küçükaslan, Ali Reha Ağaoğlu, Serhan Serhat Ay, Duygu Kaya, Mustafa Somali, and Selim Aslan. "The Effects of Separate and Combined Use of PGF2α and GnRH Hormones and the Addition of Βeta-Carotene on Fertility Parameters in Dairy Cows with Ovarian Cysts." Acta Scientiae Veterinariae 46, no. 1 (August 15, 2018): 9. http://dx.doi.org/10.22456/1679-9216.84205.

Full text

Abstract:

Background: Ovarian cysts are commonly observed pathologies, which interfere with normal cyclic activity and adversely affect fertility in cows. Beta-carotene is effective in the reduction of reproductive problems by inducing the natural defence mechanisms of the body. There are several methods that can be used for the treatment of ovarian cysts. The separate and combined use of GnRH and PGF2α commonly uses in the treatment of ovarian cysts. Therefore, in the presented study the effects of Beta-carotene (βC) addition for the treatment of ovarian cysts either with GnRH solely or GnRH and PGF2α in combination on the fertility parameters of dairy cows were investigated.Materials, Methods & Results: Seventy-six Holstein Friesian cows having ovarian cysts diagnosed by ultrasonography (USG) were divided into three groups. Cows in Group I (GI, n = 27), were injected with GnRH (Buserelin acetate, 5 mL, im), PGF2α (Tiaprost-trometamol, 5 mL, im) and βC (20 mL/cow, into 4 regions by im route). In Group II (GII, n = 25) GnRH (Buserelin acetate, 5 mL, im) and PGF2α (Tiaprost-trometamol, 5mL, im) were administrated while GnRH (Buserelin acetate, 5 mL, im) solely in Group III (GIII, n = 24). Cysts were monitored via USG, and blood samples were collected on the on day of treatment (day 0) and on the 7th and 14th days following the administrations. Cows shoving oestrous were inseminated and pregnancy diagnoses were performed on the 40th day following insemination. Treatment results showed that there were statistically no significant differences between GI and GII (P > 0.05). Only numerical difference obtained in time from therapy to pregnancy and overall pregnancy index (P > 0.05). Overall pregnancy rate (85 %), first service pregnancy rates (40 %) and overall pregnancy index (2.11) in GI were found significantly higher than GIII (53.3 %; 20 %; 4.12) [P < 0.05]. No significant difference was observed in progesterone (P4) levels between the groups (P > 0.05). It was found that βC administrations significantly increased βC levels in GI than GII and GIII on the 7th and 14th days (P < 0.05).Discussion: One of the most common problems encountered in modern dairy production is the development of ovarian cysts. Treatments for ovarian cyst are numerous and variable, and have changed considerably over the years. In the present study, GnRH and PGF2α were administered together as a combination, and as a result of this combined use, higher percentages were obtained for both pregnancy rate and fertility parameters in GI and GII, in comparison to the group administered with GnRH alone (GIII). Better outcome from combination therapy (GnRH and PGF2α) may be due to the fact that luteal thickening in the walls of cysts was determined by ultrasonography, but P4 values were not identified immediately and the treatments were not categorized in accord with these values. No statistically significant differences were determined between GI and GII concerning the fertility parameters investigated, however numerical and proportional differences were observed. βC levels were significantly higher on day 7 and 14 after treatment in GI which were administered βC additionally to the treatment protocol for ovarian cysts. This statistical difference suggests that administration of βC in combination therapy is also effective in the treatment of ovarian cysts. In conclusion, it was determined that high pregnancy rates were obtained by the combined treatment of ovarian cysts (GnRH + PGF2α) and number of inseminations per conception were at desired limits. Better percentile and numerical fertility parameters were achieved in the group, which additionally received βC, high numbers of infertility cases, βC supplementation could be a viable option for treatment.

APA, Harvard, Vancouver, ISO, and other styles

37

Matsubara, Kazutaka, Takeo Kuriki, Hidetoshi Arima, Koutarou Wakamatsu, Tetsumi Irie, and Kaneto Uekama. "Possible use of diethyl-.BETA.-cyclodextrin in preparation of sustained-release oily injection of buserelin acetate (LHRH agonist)." Drug Delivery System 5, no. 2 (1990): 95–99. http://dx.doi.org/10.2745/dds.5.95.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Chenault, John R. "Effect of Fertirelin Acetate or Buserelin on Conception Rate at First or Second Insemination in Lactating Dairy Cows." Journal of Dairy Science 73, no. 3 (March 1990): 633–38. http://dx.doi.org/10.3168/jds.s0022-0302(90)78714-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Kawamura, Naoki, Fumihiro Ito, Tomoyuki Ichimura, Sachiko Shibata, Naohiko Umesaki, and Sachio Ogita. "Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment." Fertility and Sterility 68, no. 4 (October 1997): 632–36. http://dx.doi.org/10.1016/s0015-0282(97)00273-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Ravhon, A. "Dynamic assays of inhibin B and oestradiol following buserelin acetate administration as predictors of ovarian response in IVF." Human Reproduction 15, no. 11 (November 1, 2000): 2297–301. http://dx.doi.org/10.1093/humrep/15.11.2297.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Matsubara, K., T. Irie, and K. Uekama. "Controlled release of the LHRH agonist buserelin acetate from injectable suspensions containing triacetylated cyclodextrins in an oil vehicle." Journal of Controlled Release 31, no. 2 (September 1994): 173–80. http://dx.doi.org/10.1016/0168-3659(94)00030-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Brown-Douglas, C. G., E. C. Firth, T. J. Parkinson, and P. F. Fennessy. "LH and testosterone responses to five doses of a GnRH analogue (buserelin acetate) in 12-month-old Thoroughbred colts." Theriogenology 61, no. 6 (April 2004): 1051–60. http://dx.doi.org/10.1016/j.theriogenology.2003.05.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Mori, Hiroyuki, Yuji Taketani, Tsuguo Uemura, Akira Miyake, and Toshiro Tango. "Rates of Endometriosis Recurrence and Pregnancy 1 Year after Treatment with Intranasal Buserelin Acetate (Suprecur®) (A Prospective Study)." Journal of Obstetrics and Gynaecology Research 25, no. 3 (June 1999): 153–64. http://dx.doi.org/10.1111/j.1447-0756.1999.tb01141.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Ravhon, A., R. Aurell, S. Lavery, R. Margara, and R. M. L. Winston. "P-069. The implication of delayed suppression using buserelin acetate and recombinant FSH in a long-protocol IVF programme." Human Reproduction 14, Suppl_3 (June 1999): 175. http://dx.doi.org/10.1093/humrep/14.suppl_3.175.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

MATSUBARA, Kazutaka, Tetsumi IRIE, and Kaneto UEKAMA. "Spectroscopic Characterization of the Inclusion Complex of a Luteinizing Hormone-Releasing Hormone Agonist, Buserelin Acetate, with Dimethyl-.BETA.-cyclodextrin." CHEMICAL & PHARMACEUTICAL BULLETIN 45, no. 2 (1997): 378–83. http://dx.doi.org/10.1248/cpb.45.378.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Silva, Rossane Pereira da, Karen Martins Leão, Moraima Castro Rodrigues, Thaisa Campos Marques, Natalia Do Carmo Silva, and Marco Antônio De Oliveira Viu. "Administration of GnRH on the day of fixed-time artificial insemination (FTAI) and melengestrol acetate (MGA) administration after ftai in non-suckling nelore cattle." Semina: Ciências Agrárias 36, no. 5 (October 21, 2015): 3149. http://dx.doi.org/10.5433/1679-0359.2015v36n5p3149.

Full text

Abstract:

<p>The present study evaluated the effect of administering buserelin acetate (GnRH) at the time of fixed-time artificial insemination (FTAI), along with the effect of oral administration of melengestrol acetate (MGA) after FTAI on conception rates in non-suckling Nelore cattle. In Experiment I, the effect of GnRH application at the time of FTAI was evaluated, as was administration of MGA from the 13th through the 18th day following FTAI (D24 to D29 after the initiation of the FTAI protocol). Experiment I was performed in 215 non-suckling cattle of the Nelore breed, divided into four experimental groups: Control group: 56 cows subjected to FTAI without GnRH injection; GnRH group: 51 cows subjected to GnRH at the time of FTAI; MGA Group: 57 cows subjected to FTAI without the application of GnRH with mineral supplementation and the addition of 2.28 g of MGA® Premix per cow per day from D24 to D29 after the initiation of the FTAI protocol; MGA and GnRH group: 51 cows subjected to GnRH injection at the time of FTAI, with mineral supplementation and the addition of 2.28 g of MGA® Premix per cow per day from D24 to D29 after the initiation of the FTAI protocol. In Experiment II, the effect of providing MGA five to ten days after FTAI was evaluated in 196 non-suckling pluriparous Nelore cows, divided into two groups: Control group: 104 cows subjected to FTAI, not supplemented with MGA; treated group: 92 cows supplemented with the addition of 2.28 g of MGA® Premix per cow per day from D15 to D20 after the initiation of the FTAI protocol. Diagnosis of gestation was carried out 45 days after FTAI. Both experiments were conducted using a completely randomised design and analysed via the SAS MIXED procedure. In Experiment I, the control group displayed a lower conception rate (32.1%) compared with the groups administered GnRH, MGA, and both MGA and GnRH, which were respectively provided with MGA after FTAI (45.6%), GnRH at the time of FTAI (50.9%), and the combination of the two treatments (50.9%) (P<0.05). In Experiment II, the control group displayed a higher conception rate (40.38%) compared with the group receiving MGA post-FTAI (18.48%) (P<0.05). It was concluded that the injection of buserelin acetate (GnRH) at the time of FTAI and the oral administration of MGA® Premix from the 13th to the 18th day after FTAI increased the conception rates in non-suckling Nelore cattle. However, when MGA® Premix was administered orally from the fifth to tenth day post-FTAI, conception rates in non-suckling Nelore cattle were reduced.</p>

APA, Harvard, Vancouver, ISO, and other styles

47

Lejeune, Bernard, Patricia Barlow, Francoise Puissant, Annick Delvigne, Michel Vanrysselberge, and Fernand Leroy. "Use of buserelin acetate in an in vitro fertilization program: a comparison with classical clomiphene citrate-human menopausal gonadotropin treatment." Fertility and Sterility 54, no. 3 (September 1990): 475–81. http://dx.doi.org/10.1016/s0015-0282(16)53765-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Uekama, Kaneto, Hidetoshi Arima, Tetsumi Irie, Kazutaka Matsubara, and Takeo Kuriki. "Sustained release of buserelin acetate, a luteinizing hormone-releasing hormone agonist, from an injectable oily preparation utilizing ethylated β-cyclodextrin." Journal of Pharmacy and Pharmacology 41, no. 12 (December 1989): 874–76. http://dx.doi.org/10.1111/j.2042-7158.1989.tb06393.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Lejeune, B., P. Barlow, F. Puissant, A. Delvigne, M. Vanrysselberge, and F. Leroy. "Use of buserelin acetate in an in vitro fertilization program: A comparison with classical clomiphene citrate-human menopausal gonadotropin treatment." International Journal of Gynecology & Obstetrics 35, no. 3 (July 1991): 282. http://dx.doi.org/10.1016/0020-7292(91)90306-p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Fedele, Luigi, Fabio Parazzini, Enrico Radici, Luca Bocciolone, Stefano Bianchi, Cosetta Bianchi, and Giovanni Battista Candiani. "Buserelin acetate versus expectant management in the treatment of infertility associated with minimal or mild endometriosis: A randomized clinical trial." American Journal of Obstetrics and Gynecology 166, no. 5 (May 1992): 1345–50. http://dx.doi.org/10.1016/0002-9378(92)91602-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!